Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.75 |
| ▸ | CA2 | P00918 | 13/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CA12 | O43570 | 4/20 | 0.63 |
| ▸ | CA9 | Q16790 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MITF | O75030 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.61 |
| ▸ | CA4 | P22748 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31195239 | 0.88 | CA1 (0.71) | CA1CA2KMT2AMEN1CA12 | |
| SCHEMBL25738602 | 0.86 | CA1 (1.00) | CA1CA2KMT2AMEN1CA12 | |
| SCHEMBL25738387 | 0.84 | CA1 (0.80) | CA1CA2KMT2AMEN1CA12 | |
| SCHEMBL25242669 | 0.84 | ALDH1A1 (0.61) | CA1CA2KMT2AMEN1MAPT | |
| SCHEMBL10711401 | 0.83 | CA1 (0.78) | CA1CA2KMT2ACA12CA9 | |
| SCHEMBL7486448 | 0.82 | CA1 (0.71) | CA1CA2KMT2AMEN1CA12 | |
| SCHEMBL11802189 | 0.81 | ALDH1A1 (0.67) | KMT2AMEN1MAPTALDH1A1MITF | |
| SCHEMBL31195222 | 0.81 | LMNA (0.69) | KMT2AMEN1MAPTALDH1A1MITF | |
| SCHEMBL13764399 | 0.81 | CA1 (0.72) | CA1CA2KMT2AMEN1CA12 | |
| SCHEMBL188860 | 0.81 | CA1 (0.74) | CA1CA2KMT2ACA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719413-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | Animol Discovery, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092070-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY INC (US) | 2026-04-02 | — | — | US | disclosed |
| WO-2024246837-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| CN-116670143-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4225447-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-107922345-B | Arylsulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use | 圣诺康生命科学公司 | 2021-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CA1 4871/4885CA2 2703/4885KMT2A 4667/4885 |
| US-20260092070-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | JAK1, JAK3, JAK2 | CA1 2926/4885CA2 1072/4885KMT2A 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.